A new focus on thyrosine kinases inhibitors in eosinophilic granulomatosis with polyangiitis

Clin Exp Rheumatol. 2021 Mar-Apr;39 Suppl 129(2):180-181. doi: 10.55563/clinexprheumatol/rrjt9m. Epub 2020 Dec 2.

Authors

Paola Triggianese¹, Arianna D'Antonio², Paola Conigliaro², Francesco Buccisano³, Giulia Lavinia Fonti², Maria Sole Chimenti², Roberto Perricone²

Affiliations

¹ Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy. triggianese@med.uniroma2.it.
² Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
³ Haematology, Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.

PMID: 33338003
DOI: 10.55563/clinexprheumatol/rrjt9m

No abstract available

Publication types

Letter
Comment

MeSH terms

Churg-Strauss Syndrome* / diagnosis
Churg-Strauss Syndrome* / drug therapy
Eosinophils
Granulomatosis with Polyangiitis* / diagnosis
Granulomatosis with Polyangiitis* / drug therapy
Humans
Immunosuppressive Agents

Substances

Immunosuppressive Agents